BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15083212)

  • 21. Indirect immunofluorescence on HEp-2000 substrate is a sensitive method for detecting anti-Ro/SSA antibodies in patients with lupus erythematosus and/or photosensitivity.
    Cozzani E; Drosera M; Siccardi M; Babbini G; Parodi A
    J Rheumatol; 2008 Jul; 35(7):1320-2. PubMed ID: 18528967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of antinuclear antibodies: assessment of different test systems.
    Kern P; Kron M; Hiesche K
    Clin Diagn Lab Immunol; 2000 Jan; 7(1):72-8. PubMed ID: 10618281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of Indirect immunofluorescence (IIF) alone as a screening method for antinuclear antibody in connective diseases in India's sub-Himalayan region.
    Kalita D; Rekha US; Raj AK; Mahanta P; Gupta P; Deka S
    Indian J Pathol Microbiol; 2022; 65(4):873-878. PubMed ID: 36308197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical evaluation of quantitative measurement of various antinuclear antibodies by enzyme immunoassay].
    Miyawaki S
    Rinsho Byori; 1994 May; 42(5):467-75. PubMed ID: 8022075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibody detection with indirect immunofluorescence on HEp-2 cells: starting serum dilutions for systemic rheumatic diseases.
    González DA; León AC; Varela AR; García MG; Rahola Mde S; Pérez Mdel C; Hernández AG; Falcón MJ; Díaz BB
    Immunol Lett; 2011 Oct; 140(1-2):30-5. PubMed ID: 21684306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Serological diagnosis of systemic connective tissue inflammation; a new immunofluorescence method for demonstrating antinuclear antibodies].
    Scagliusi P; Laghezza D; Ferrari G; Fasiello V; De Lucia M
    Minerva Med; 1981 Jan; 72(2):81-90. PubMed ID: 7007926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From ANA to ENA: how to proceed?
    Damoiseaux JG; Tervaert JW
    Autoimmun Rev; 2006 Jan; 5(1):10-7. PubMed ID: 16338206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a new screening strategy for anti-extractable nuclear antigen antibodies.
    Van Praet JT; Vander Cruyssen B; Bonroy C; Smith V; Delanghe J; De Keyser F
    Clin Exp Rheumatol; 2009; 27(6):971-6. PubMed ID: 20149314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus.
    Agarwal S; Harper J; Kiely PD
    Lupus; 2009 Apr; 18(5):407-12. PubMed ID: 19318392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of infants from mothers with anti-SSA/Ro antibodies.
    Motta M; Rodriguez-Perez C; Tincani A; Lojacono A; Chirico G
    J Perinatol; 2007 May; 27(5):278-83. PubMed ID: 17363909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of antinuclear antibodies (ANA), antibodies to double stranded DNA (anti-dsDNA) and antibodies to extractable nuclear antigens (anti-ENA) in Greek patients.
    Stamouli M; Skliris A; Reppa D; Maganaki E; Totos G
    Clin Lab; 2013; 59(3-4):283-91. PubMed ID: 23724616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The importance of antinuclear (ABA) and anti-double stranded dna (anti-dsDNA) antibodies in the diagnosis of connective tissue diseases.].
    Yilmaz O; Karaman M; Ergon MC; Bahar IH; Yuluğ N
    Turkiye Parazitol Derg; 2005; 29(4):287-90. PubMed ID: 17124690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing.
    Peene I; Meheus L; Veys EM; De Keyser F
    Ann Rheum Dis; 2001 Dec; 60(12):1131-6. PubMed ID: 11709455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection and identification of antinuclear antibodies (ANA) in a large community hospital.
    Verstegen G; Duyck MC; Meeus P; Ravelingien I; De Vlam K
    Acta Clin Belg; 2009; 64(4):317-23. PubMed ID: 19810418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of antinuclear antibody connective tissue disease screen.
    López-Hoyos M; Rodríguez-Valverde V; Martinez-Taboada V
    Ann N Y Acad Sci; 2007 Aug; 1109():322-9. PubMed ID: 17785321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the LIAISON ANA screen assay for antinuclear antibody testing in autoimmune diseases.
    Ghillani P; Rouquette AM; Desgruelles C; Hauguel N; Le Pendeven C; Piette JC; Musset L
    Ann N Y Acad Sci; 2007 Aug; 1109():407-13. PubMed ID: 17785329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests.
    Hoffman IE; Peene I; Veys EM; De Keyser F
    Clin Chem; 2002 Dec; 48(12):2171-6. PubMed ID: 12446473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basics in standardization and practical applications of immunofluorescent microscopy: standardization of antinuclear antibody tests.
    Beutner EH; Kumar V; Greenlee P
    Lab Res Methods Biol Med; 1983; 8():49-70. PubMed ID: 6358746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus.
    Faria AC; Barcellos KS; Andrade LE
    J Rheumatol; 2005 Jul; 32(7):1267-72. PubMed ID: 15996063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.